Cure8 research brief
The study compares ustekinumab effectiveness between biologic‑naïve and biologic‑experienced Crohn’s patients and links clinical response to better quality of life and reduced anxiety — information relevant when considering treatment sequencing.
Adult Crohn’s patients (especially those considering or using ustekinumab), clinicians prescribing biologics, and researchers of biologic sequencing and patient‑reported outcomes.
This Frontiers in Gastroenterology abstract reports data from 61 CD patients treated with ustekinumab and followed through 32 weeks.
Inflammatory and nutritional markers improved in both groups; improvements in inflammation, CDAI and SES‑CD were greater in biologic‑naïve patients, though clinical response and remission rates were reported as similar between groups.
Patients who achieved clinical response had larger gains in IBDQ quality‑of‑life scores, and anxiety (HADS‑A) fell significantly only in responders.
This is a retrospective, abstract‑level report from a single study with 61 patients and 32‑week follow-up; results are suggestive but not definitive and should be interpreted alongside larger, prospective studies and clinical guidelines.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
Ustekinumab is already approved for moderate-to-severe Crohn's disease; this real-world study reports encouraging longer-term clinical, biological, and endoscopic outcomes up to 96 weeks and suggests good treatment...
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
